Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be pr

[News]

Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.

More... (http://www.news-medical.net/news/20100605/Multiple-study-data-on-Agendias-MammaPrint-BluePrint-and-ColoPrint-assays-to-be-presented-at-2010-ASCO.aspx)